Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior (Nasdaq/LSE: INDV) has announced the release of its Q1 2025 financial results for the period ending March 31, 2025. The company has made available its earnings release and investor presentation on their corporate website www.indivior.com.
A live webcast presentation is scheduled for 13:00 BST (8:00 am ET), to be hosted by CEO Mark Crossley. Participants can access the presentation through a webcast link or join telephonically by registering through the provided registration link.
Indivior PLC (NASDAQ/LSE: INDV) has announced significant changes to its Board of Directors, following previous appointments and discussions with Oaktree Capital Management. The key changes include:
- Reducing board size to seven directors for the 2025 AGM
- Peter Bains and Jo LeCouilliard will not seek re-election
- Robert Schriesheim stepped down effective March 2, 2025
- Search for one new Independent Non-Executive Director by July 1, 2025
- Daniel Ninivaggi appointed as Chair of Nomination Committee from March 10, 2025
- Barbara Ryan to become Chair of Compensation Committee after AGM
- Discontinuation of Operational Committee
These changes follow recent appointments including Dr. David Wheadon as Chair, Daniel Ninivaggi as Independent Non-Executive Director, and Joe Ciaffoni as CEO. The company has entered an amended Relationship Agreement with Oaktree Capital Management.
Indivior PLC (INDV) has appointed Joe Ciaffoni as its new Chief Executive Officer, effective upon shareholder approval at the May 2025 AGM. Ciaffoni, 53, who joined as an Independent Non-Executive Director in December 2024, brings over 30 years of pharmaceutical and biotech experience, having previously served as President and CEO of Collegium Pharmaceutical.
Current CEO Mark Crossley will step down following his tenure since June 2020, but will remain to support the transition until at least May 2025. Under Crossley's leadership, the company strengthened its commitment to patients and expanded treatment access for substance use disorders.
Ciaffoni's appointment aims to fuel Indivior's next growth phase in addiction treatment, where the company maintains a global portfolio of OUD treatments and employs over 1,000 individuals with products available in more than 30 countries.
Indivior (NASDAQ/LSE: INDV) announced FDA approval of significant label changes for SUBLOCADE®, their treatment for moderate to severe opioid use disorder (OUD). The key updates include a rapid initiation protocol that reduces treatment initiation time from one week to one hour, and new alternative injection sites including abdomen, thigh, buttock, and back of upper arm.
The rapid initiation protocol allows healthcare providers to start SUBLOCADE treatment after a single dose of transmucosal buprenorphine and a one-hour observation period. A non-inferiority study with 729 participants demonstrated the effectiveness of rapid initiation, with 66.4% of patients in the rapid induction arm receiving a second injection compared to 54.5% in the standard induction arm. Of the study participants, 77.5% were fentanyl-positive at induction.
These changes aim to reduce treatment obstacles and improve patient adherence while maintaining SUBLOCADE's established safety profile and efficacy.
Indivior PLC (Nasdaq/LSE: INDV) has announced its financial results for the fiscal year and fourth quarter of 2024, ending December 31, 2024. The company will host a live webcast presentation at 13:00 BST (8:00 am ET), led by CEO Mark Crossley.
The earnings release and investor presentation materials are available on the company's website at www.indivior.com. Participants can join the presentation through a webcast link or register for telephonic access.
Indivior PLC (Nasdaq/LSE: INDV) announced that the FDA has delayed the final review of proposed label changes for SUBLOCADE® (buprenorphine extended-release) Injection. The PDUFA action date was originally scheduled for February 7, 2025. On February 11, 2025, the FDA informed Indivior that while there were no outstanding items to address following acceptance of the proposed label, the final review has been delayed. The proposed changes include rapid initiation protocol and alternative injection sites. The company will provide updates on the approval status as appropriate.
Indivior PLC presented significant findings at CSAM 2024 showing that rapid initiation (RI) with once-monthly SUBLOCADE improves treatment retention for opioid use disorder (OUD) patients compared to standard initiation (SI). The study of 729 participants demonstrated a 12% overall improvement in retention rates, with a 15% increase among fentanyl-positive patients.
The RI protocol involves administering SUBLOCADE within one hour of a single transmucosal buprenorphine dose, followed by a second injection after one week, versus the standard 28-day interval. The FDA has granted Priority Review for label expansion to include rapid initiation and alternative injection sites (thigh, upper arm, and buttocks), with a PDUFA date of February 7, 2025.
Indivior PLC (NASDAQ/LSE: INDV) has acknowledged a letter published by Oaktree Capital Management to its Board of Directors. The Board confirms it has been actively engaging with Oaktree in recent weeks and maintains an open-minded stance regarding proposals for value creation. Indivior, a global pharmaceutical company focused on substance use disorders (SUD) treatment, emphasizes its commitment to acting in the best interests of all shareholders while executing its strategy. The company operates in over 30 countries and employs more than 1,000 people globally.
Indivior PLC (Nasdaq/LSE: INDV) highlights key findings demonstrating the effectiveness and safety of SUBLOCADE in treating opioid use disorder (OUD). A post-hoc analysis showed that SUBLOCADE 300 mg maintenance dose significantly increased opioid abstinence in injecting participants compared to 100 mg dose. The CoLAB Study demonstrated 96-week treatment maintenance with improvements in abstinence, depression, and quality of life. Research identified telemedicine as a common solution during COVID-19 for overcoming access barriers, though challenges persist. Multiple real-world evidence presentations addressed various aspects of OUD treatment, including ER visits, healthcare utilization, and treatment outcomes. Only 18% of the nearly 6 million people with OUD received MOUD treatment in 2023.
Indivior PLC (Nasdaq/LSE: INDV) has announced its financial results for Q3 2024, ending September 30, 2024. The company has made available its earnings release and investor presentation on www.indivior.com. CEO Mark Crossley will host a live webcast presentation at 13:00 BST (8:00 am ET). Participants can join the presentation through a webcast link or register for telephonic access.